Program
HRS-2189
A development code. Also written as “HRS-2189 Tablet” and “HRS-2189 Tablets”.
In Jiangsu HengRui Medicine's pipeline, KAT6
. Its studies are led by Jiangsu HengRui Medicine.
Furthest: phase 1, since Apr 24, 20232 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 21 open or running | phase 1since Apr 24, 2023 | Apr 24, 2023 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-2189
, phase 2, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 24, 2023First study: phase 1 study in Advanced Malignant TumorFirst studyNCT05851092 · 60 planned · China
- Jun 5, 2026Phase 1 study in Malignant Solid TumorNCT07639905 · 28 enrolled · China
TargetBeta
“KAT6”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| prifetrastat | Pfizer | phase 3 | 10 |
| KAT6A/B Inhibitor BG-75202rule | BeOne Medicines | phase 1 | 2 |
| KAT6 Inhibitor OP-3136rule | olema-pharmaceuticals-inc | phase 1 | 1 |
| KAT6/KAT7 Inhibitor PF-08032562rule | Pfizer | phase 1 | 1 |
| KAT6/KAT7 Inhibitor IDE574rule | ideaya-biosciences | phase 1 | 1 |
| HLX97 | Fosun Pharma | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07639905Malignant Solid Tumor · China | 1 | Completed | Aug 6, 2026 | 28 |
| NCT05851092Advanced Malignant Tumor · China | 1 | Recruiting | Dec 31, 2025 | 60 |
How it is read
Names in the registry
- “HRS-2189 Tablet”, 1 entry
- “HRS-2189 Tablets”, 1 entry
Codes read as this program: HRS2189.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.